^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    milciclib (TZLS-201)

    i
    Other names: TZLS-201, PHA-848125, PHA 848125C, PHA-125, PHA-848125AC
    Associations

    News

    Trials
    Company:
    Nerviano Medical Sciences, Tiziana Life Sci
    Drug class:
    pan-CDK inhibitor
    Associations

    News

    Trials
    7ms
    Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma. (PubMed, Genomics)
    The results also showed that milciclib might inhibit the proliferation and migration of KYSE150 and KYSE510 cells by targeting CDKN2A. In conclusion, the abovementioned CUGs and CRGs play a crucial role in tumorigenesis and cancer progression in ESCC, indicating their potential as therapeutic targets.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BTLA (B And T Lymphocyte Associated) • DLAT (Dihydrolipoamide S-Acetyltransferase) • MELTF (Melanotransferrin) • PRRX1 (Paired Related Homeobox 1) • FDX1 (Ferredoxin 1) • LIAS (Lipoic Acid Synthetase) • LIPT1 (Lipoyltransferase 1) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1)
    |
    milciclib (TZLS-201)
    over1year
    Milciclib in Combination With Gemcitabine in Advanced NSCLC (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Tiziana Life Sciences LTD
    New P2 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13
    |
    gemcitabine • milciclib (TZLS-201)